IMV INC (IMV) Stock Price, Quote, News and Overview
NASDAQ:IMV - Nasdaq - CA44974L3011 - Common Stock - Currency: USD
IMV Quote, Performance and Key Statistics
0.8225
-0.02 (-2.55%)
The current stock price of IMV is 0.8225 USD. In the past month the price increased by 52.46%. In the past year, price decreased by -93.09%.
IMV Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About IMV
Company Profile
IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company is headquartered in Dartmouth, Nova Scotia and currently employs 63 full-time employees. The company went IPO on 2007-10-24. The firm is focused on developing a portfolio of therapies based on DPX, an immune-educating technology platform, that is designed to inform a specific anti-tumor immune response, offering benefit to patients with solid or hematological cancers. Its lead candidate, maveropepimut-S (MVP-S) is a DPX-based immunotherapy that targets survivin-expressing cells for elimination by educated, cytotoxic T cells. Its other candidates include DPX-RSV and DPX-COVID-19. DPX-RSV is a DPX-based vaccine candidate targeting the respiratory syncytial virus (RSV) strain A. The company is focused on developing DPX-COVID-19, a vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using its DPX platform. The firm is also developing maveropepimut-S for the treatment of breast and ovarian cancer, as well as for Diffuse large B-cell lymphoma (DLBCL) and other malignancies.
Company Info
IMV INC
130 Eileen Stubbs Ave Suite 19
Dartmouth NOVA SCOTIA B3B 2C4 CA
CEO: Frederic Ors
Employees: 63
Company Website: https://imv-inc.com/
Phone: 19024921819.0
IMV INC / IMV FAQ
What is the stock price of IMV INC today?
The current stock price of IMV is 0.8225 USD. The price decreased by -2.55% in the last trading session.
What is the ticker symbol for IMV INC stock?
The exchange symbol of IMV INC is IMV and it is listed on the Nasdaq exchange.
On which exchange is IMV stock listed?
IMV stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for IMV INC stock?
7 analysts have analysed IMV and the average price target is 21.8 USD. This implies a price increase of 2550.76% is expected in the next year compared to the current price of 0.8225. Check the IMV INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is IMV INC worth?
IMV INC (IMV) has a market capitalization of 9.63M USD. This makes IMV a Nano Cap stock.
How many employees does IMV INC have?
IMV INC (IMV) currently has 63 employees.
What are the support and resistance levels for IMV INC (IMV) stock?
IMV INC (IMV) has a support level at 0.54 and a resistance level at 0.91. Check the full technical report for a detailed analysis of IMV support and resistance levels.
Is IMV INC (IMV) expected to grow?
The Revenue of IMV INC (IMV) is expected to decline by -80.66% in the next year. Check the estimates tab for more information on the IMV EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy IMV INC (IMV) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IMV, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IMV, evaluating the profitability, health, valuation and growth aspects
- IMV INC (IMV) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- IMV INC (IMV) Sales and EPS estimates to see what analysts future expectations are.
- IMV INC (IMV) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- IMV INC (IMV) Insider and Institutional Ownership to learn about the owners and their transactions.
- IMV INC (IMV) Stock Chart to make your own analysis
- IMV INC (IMV) Latest news and press-releases to stay up to date.
Does IMV INC (IMV) stock pay dividends?
IMV does not pay a dividend.
When does IMV INC (IMV) report earnings?
IMV INC (IMV) will report earnings on 2023-05-11, before the market open.
What is the Price/Earnings (PE) ratio of IMV INC (IMV)?
IMV INC (IMV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.59).
IMV Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to IMV. When comparing the yearly performance of all stocks, IMV is a bad performer in the overall market: 98.15% of all stocks are doing better.
IMV Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IMV. IMV may be in some trouble as it scores bad on both profitability and health.
IMV Financial Highlights
Over the last trailing twelve months IMV reported a non-GAAP Earnings per Share(EPS) of -4.59. The EPS increased by 4.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
IMV Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to IMV. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 20.34% and a revenue growth -80.66% for IMV